Arxis Securities’s SELLAS Life Sciences SLS Stock Holding History

Arxis Securities’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-9	Closed	-$25K	–	71
2016 Q4	$25K	Buy	+9	New	+$52.3K	0.03%	49

Other funds holding SLS

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Arxis Securities's SLS Position: Q1 2017 in Review

Arxis Securities sold out of SELLAS Life Sciences (SLS) in Q1 2017, closing a stake of 9 shares — an estimated $25K sold.

Arxis Securities first reported a position in SLS in Q4 2016 and held it in 1 quarter. The position peaked at $25K in Q4 2016. 50 funds tracked by Wall St. Rank hold SLS as of Q1 2017.

Arxis Securities reported no remaining SELLAS Life Sciences position as of Q1 2017 after selling out during the quarter.
Arxis Securities sold 9 SELLAS Life Sciences shares in Q1 2017, an estimated $25K.
Arxis Securities first reported a position in SELLAS Life Sciences in Q4 2016 and held it in 1 quarter.
Arxis Securities's SELLAS Life Sciences position peaked at $25K in Q4 2016.
50 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2017.

Based on Arxis Securities's 13F filing for Q1 2017, filed 8 May 2017.